Pear Therapeutics to Present at UBS Global Healthcare Conference
May. 17, 2018
BOSTON--(BUSINESS WIRE)--May 17, 2018--Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 22 at 4:00 p.m. EST at the Grand Hyatt New York.
Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions.
About Pear Therapeutics Pear Therapeutics is the leader in FDA-authorized prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-authorized 12-week prescription therapeutic for Substance Use Disorder to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O™ for opioid use disorder and additional prescription digital therapeutics in schizophrenia (THRIVE™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia. For more details, please see www.peartherapeutics.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180517005264/en/
CONTACT: Media and Investors:
Pear Therapeutics, Inc.
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL FDA
SOURCE: Pear Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 05/17/2018 08:00 AM/DISC: 05/17/2018 08:01 AM